The Big Winner From the Aurora Cannabis-Organigram Deal: Curaleaf
Organigram is valuing Aurora Cannabis more highly than Curleaf, but that doesn't mean it's the best option for shareholders in the long run.
·
The Motley Fool
Oklo Is Down 86% From Its High. Will Shares Soar When Meta’s Reactor Comes Online?
SMR stocks are getting hammered alongside AI stocks.
·
The Motley Fool
Why IonQ Stock Plummeted 31.5% in October
It wasn't only Halloween that had investors scared in October.
·
The Motley Fool
Yikes! CEO Jensen Huang Just Delivered Shocking News That Could Serve as an ‘Overhang’ on the Stock
Nvidia's board of directors is launching an investigation into whether CEO Jensen Huang was the target of a "foreign intelligence effort."
·
The Motley Fool
2 Hidden Downsides to the 3.6% 2027 Social Security COLA
More money now could come at a cost later.
·
The Motley Fool
Will a Federal Reserve Interest Rate Hike Trigger a Recession? Here’s What History Says.
Trading activity implies a 70% probability that the federal funds rate will be higher before year-end.
·
The Motley Fool
This Under-the-Radar Cryptocurrency Is Up Big So Far in 2026. But Is It a Buy?
Monero's recent success is happening as regulators are trying to ban it.
·
The Motley Fool
